Author

Madeline Wu

Aaron Diamond AIDS Research Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 11

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 9 Organism:human· 8 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

David D. HoiD· 11 shared Ian A. MellisiD· 10 shared Aubree L. GordoniD· 7 shared Hsiang HongiD· 7 shared Qian WangiD· 7 shared Yicheng GuoiD· 7 shared Anthony D. BoweniD· 5 shared Carmen GherasimiD· 5 shared

Activity by Year

2024-2026 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersMicrobiology

David D. HoORCID

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

A Monoclonal Antibody Panel to Track Antigenic Evolution of SARS-CoV-2 JN.1 Subvariants

Hsiang Hong, Madeline Wu, Sue Chong, Jian Yu, Ian A. Mellis, Chien-Yu Huang, Qian Wang, Yaoxing Huang, Yicheng Guo, David D. Ho

The paper develops a monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants and identifies differences in antibody-evasion profiles between JN.1 and BA.3.2 lineages.

bioRxiv · Oct 6, 2026 · PreprintMicrobiology

SARS-CoV-2 BA.3.2.2 is more evasive of neutralization by sera from young children

Madeline Wu, Hsiang Hong, Yicheng Guo, Kristin Daniel, Ryan Hisner, Marc C. Johnson, Aubree L. Gordon, David D. Ho, Ian A. Mellis

This study finds that young children have lower neutralizing antibody titers against BA.3.2.2 compared to adults, despite similar titers against dominant variants, suggesting age-related differences in susceptibility.

bioRxiv · Jun 3, 2026 · PreprintMicrobiology

A Panel of Human Monoclonal Antibodies for Tracking the Antigenic Evolution of Influenza H5N1 Clade 2.3.4.4b

Hsiang Hong, Nicholas C. Morano, Madeline Wu, Sue Chong, Jian Yu, Yaoxing Huang, Manoj S. Nair, Zhiteng Li, Chih-Chen Tzang, Jordan E. Becker, C H Wang, Lawrence S. Shapiro, Peter D. Kwong, Yicheng Guo, David D. Ho

This study generates 19 human monoclonal antibodies to track antigenic evolution of H5N1 clade 2.3.4.4b, identifying epitope-specific neutralization patterns and antigenic differences between viral genotypes.

bioRxiv · May 15, 2026 · PreprintMicrobiology

LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting

Ian A. Mellis, Madeline Wu, Hsiang Hong, Anthony D. Bowen, Kristin Daniel, Carmen Gherasim, Virginia Pierce, Michael T. Yin, Aubree L. Gordon, Yicheng Guo, David D. Ho

This study evaluates the effectiveness of LP.8.1-targeted mRNA vaccines in boosting neutralizing antibodies and reducing immune imprinting from ancestral SARS-CoV-2 strains.

PLoS Pathogens · May 11, 2026Peer-reviewedMicrobiology

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individuals

Ian A. Mellis, Madeline Wu, Kristin Daniel, Hsiang Hong, Yicheng Guo, David D. Ho

This study evaluates VYD2311, a new monoclonal antibody, showing it neutralizes multiple SARS-CoV-2 variants more effectively than pemivibart, making it a potential candidate for immunocompromised individuals.

bioRxiv · Apr 1, 2026 · PreprintMicrobiology

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

Ian A. Mellis, Madeline Wu, Hsiang Hong, Chih-Chen Tzang, Anthony D. Bowen, Qian Wang, Carmen Gherasim, Virginia Pierce, Jayesh Shah, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, Yicheng Guo, David D. Ho

This study compares antibody evasion and receptor binding of SARS-CoV-2 subvariants, finding that LP.8.1.1 has high ACE2 affinity, while NB.1.8.1 and XFG show greater antibody evasion.

Cell Reports · Nov 24, 2025Peer-reviewedMicrobiology

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2

Qian Wang, Yicheng Guo, Ryan G. Casner, Jian Yu, Manoj S. Nair, Jerren Ho, Eswar R. Reddem, Ian A. Mellis, Madeline Wu, Chih-Chen Tzang, Hsiang Hong, Yaoxing Huang, Lawrence S. Shapiro, Lihong Liu, David D. Ho

This study optimizes a human monoclonal antibody to enhance its neutralization of SARS-CoV-2 variants, including subvariants XEC and LP.8.1, through structural analysis and engineering.

Nature Communications · Jul 4, 2025Peer-reviewedMicrobiology

Do Existing COVID-19 Vaccines Need to Be Updated in 2025?

Ian A. Mellis, Madeline Wu, Qian Wang, Anthony D. Bowen, Carmen Gherasim, Riccardo Valdez, Jayesh Shah, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, Yicheng Guo, David D. Ho

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

bioRxiv · May 2, 2025 · PreprintMicrobiology

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC

Qian Wang, Yicheng Guo, Ian A. Mellis, Madeline Wu, Hiroshi Mohri, Carmen Gherasim, Riccardo Valdez, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, David D. Ho

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

Cell Reports · Apr 1, 2025Peer-reviewedMicrobiology

KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2

Qian Wang, Ian A. Mellis, Madeline Wu, Anthony D. Bowen, Carmen Gherasim, Riccardo Valdez, Jayesh Shah, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, Yicheng Guo, David D. Ho

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

The Lancet Infectious Diseases · Feb 4, 2025Peer-reviewedMicrobiology

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

Qian Wang, Ian A. Mellis, Jerren Ho, Anthony D. Bowen, Theresa Kowalski-Dobson, Riccardo Valdez, Phinikoula S. Katsamba, Madeline Wu, Caitlin Lee, Lawrence S. Shapiro, Aubree Gordon, Yicheng Guo, David D. Ho, Lihong Liu

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

Emerging Microbes & Infections · Sep 11, 2024Peer-reviewedMicrobiology